Reference Detail

Ref Type

Journal Article

PMID

(33593882)

Authors

Nguyen TT, Ramsay L, Ahanfeshar-Adams M, Lajoie M, Schadendorf D, Alain T, Watson IR

Title

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Clinical cancer research : an official journal of the American Association for Cancer Research	27	12	2021 Jun 15	3432-3442	Clin Cancer Res

URL

Abstract Text

Next-generation sequencing studies and CRISPR-Cas9 screens have established mutations in the IFNγ-JAK-STAT pathway as an immune checkpoint inhibitor (ICI) resistance mechanism in a subset of patients with melanoma. We hypothesized ICI resistance mutations in the IFNγ pathway would simultaneously render melanomas susceptible to oncolytic virus (OV) therapy.Cytotoxicity experiments were performed with a number of OVs on a matched melanoma cell line pair generated from a baseline biopsy and a progressing lesion with complete JAK2 loss from a patient that relapsed on anti-PD-1 therapy, in melanoma lines following JAK1/2 RNA interference (RNAi) and pharmacologic inhibition and in Jak2 knockout (KO) B16-F10 mouse melanomas. Furthermore, we estimated the frequency of genetic alterations in the IFNγ-JAK-STAT pathway in human melanomas.The melanoma line from an anti-PD-1 progressing lesion was 7- and 22-fold more sensitive to the modified OVs, herpes simplex virus 1 (HSV1-dICP0) and vesicular stomatitis virus (VSV-Δ51), respectively, compared with the line from the baseline biopsy. RNAi, JAK1/2 inhibitor studies, and in vivo studies of Jak2 KOs B16-F10 melanomas revealed a significant increase in VSV-Δ51 sensitivity with JAK/STAT pathway inhibition. Our analysis of The Cancer Genome Atlas data estimated that approximately 11% of ICI-naïve cutaneous melanomas have alterations in IFNγ pathway genes that may confer OV susceptibility.We provide mechanistic support for the use of OVs as a precision medicine strategy for both salvage therapy in ICI-resistant and first-line treatment in melanomas with IFNγ-JAK-STAT pathway mutations. Our study also supports JAK inhibitor-OV combination therapy for treatment-naïve melanomas without IFN signaling defects.See related commentary by Kaufman, p. 3278.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
HSV1-dICP0	HSV1-dICP0	1	0
VSV-delta51	VSV-delta51	3	0

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
HSV1-dICP0				HSV1-dICP0 is an oncolytic herpes simplex virus type 1 with deletion of the ICP0 gene, which may induce a cytotoxic response in tumor cells (PMID: 33593882).
VSV-delta51		VSV(M Delta 51)		VSV-delta51 is an oncolytic vesicular stomatitis virus (VSV) with a deletion of methionine 51 in the M protein, which may induce a cytotoxic response in tumor cells and an antitumor immune response (PMID: 14585354, PMID: 33593882).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
JAK2 loss	melanoma	sensitive	VSV-delta51	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with VSV-delta51 resulted in decreased cell viability in melanoma cell lines with a loss of JAK2 in culture, and resulted in an increased median survival in a syngeneic mouse model grafted with a CRISPR-mediated JAK2 knockout melanoma cell line (PMID: 33593882).	33593882
JAK2 LOH JAK2 inact mut	melanoma	predicted - sensitive	HSV1-dICP0	Preclinical - Patient cell culture	Actionable	In a preclinical study, a melanoma patient-derived cell line harboring an inactivating JAK2 mutation and JAK2 loss of heterozygosity resulted in sensitivity to treatment with an oncolytic virus, HSV1-dICP0, in culture (PMID: 33593882).	33593882
JAK2 LOH JAK2 inact mut	melanoma	predicted - sensitive	VSV-delta51	Preclinical - Patient cell culture	Actionable	In a preclinical study, a melanoma patient-derived cell line harboring an inactivating JAK2 mutation and JAK2 loss of heterozygosity resulted in sensitivity to treatment with an oncolytic virus, VSV-delta51, in culture (PMID: 33593882).	33593882
JAK2 dec exp	melanoma	predicted - sensitive	VSV-delta51	Preclinical - Cell culture	Actionable	In a preclinical study, siRNA knockdown of JAK2 in a melanoma cell line resulted in increased sensitivity to treatment with an oncolytic virus, VSV-delta51, in culture (PMID: 33593882).	33593882